Willow Lane Acquisition Corp. II
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Willow Lane Acquisition Corp. II.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Price history
Chart
Interactive price chart (TradingView).
52-week range: 9.90 $ to 10.30 $ · Last price: 10.30 $ (As of: September 30, 2026)
Key figures
Key figures at a glance
Every figure we hold for this stock, grouped by topic. The question mark next to a label explains what the number means.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 10/01/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
Comparison
Industry comparison
The stock alongside the largest companies in the same group. The median row is the middle value of the companies shown above — not of the whole industry.
Industry: Shell Companies
| Company | Market cap ($B) | P/E | EV/EBITDA | Gross Margin % | EBIT Margin % | Sales Growth (Year) % | Perf. 1Y % |
|---|---|---|---|---|---|---|---|
| Willow Lane Acquisition Corp. II WLII | 0.3 | – | 0.0 | – | 0.0 | – | – |
| Lionsgate Studios Holding Corp. LION | 3.3 | – | 5.6 | – | 0.0 | -17.6 | 60.8 |
| Churchill Capital Corp X CCCX | 0.7 | – | 0.0 | – | 0.0 | – | -51.4 |
| Drugs Made In America Acquisition II Corp. DMII | 0.7 | 78.6 | 0.0 | – | 0.0 | – | – |
| Churchill Capital Corp XI CCXI | 0.6 | – | 0.0 | – | 0.0 | – | – |
| Armada Acquisition Corp. II XRPN | 0.6 | 125.7 | 0.0 | – | 0.0 | – | 57.2 |
| Churchill Capital Corp XII CXII | 0.6 | – | 0.0 | – | 0.0 | – | – |
| Bain Capital GSS Investment Corp. BCSS | 0.6 | – | 0.0 | – | 0.0 | – | – |
| EQV Ventures Acquisition Corp. II EVAC | 0.6 | 31.1 | 0.0 | – | 0.0 | – | 3.7 |
| Median of companies shown | 0.6 | 78.6 | 0.0 | – | 0.0 | – | 30.5 |
Based on the most recently reported figures. Only stocks from the same trading venue are lined up, so the market caps are counted in one currency. Compare in a chart →
Fiscal years
Annual Figures
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
Revenue, operating income and net income per fiscal year $M
Revenue Operating income Net income
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2025 | – | 0 | 0 | 0.00 | – | 0 | 0 |
Screening
Appears in These Scanners
This stock currently matches 2 of our scanner strategies — each hit links to the scanner.
Risk & Weakness
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
AI classification
AI Rating
Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available.
The company
About the Company
Willow Lane Acquisition Corp. II konzentriert sich darauf, eine Fusion, einen Zusammenschluss, einen Aktientausch, einen Vermögenserwerb, einen Aktienkauf, eine Reorganisation oder einen ähnlichen Unternehmenszusammenschluss mit einem oder mehreren Unternehmen durchzuführen. Das Unternehmen wurde 2025 gegründet und hat seinen Sitz in New York, New York.
- Headquarters
- New York, NY
- Address
- 250 West 57th Street, 10107 New York, United States
- Phone
- 646 565 3861
- IPO Date
- 04/06/2026
- ISIN
- KYG9675K1031
Management
| Name | Title | Birth Year |
|---|---|---|
| B. Luke Weil | CEO & Chairman | 1980 |
| George Peng CFA | Chief Financial Officer | 1970 |
| Marjorie Ivette Hernandez | Chief Operating Officer | 1980 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Data as of: September 30, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.